FDA Clears Inovio's First Product, VOCERYQ for RRP; Launch in ~60 Days
INO has more than doubled off its 52-week low of $0.563 on elevated volume (15× avg).
Summary
Inovio received FDA accelerated approval for VOCERYQ in adults with recurrent respiratory papillomatosis — its first approved product — with orders and shipping expected in about 60 days and full field deployment in Q1 2027. The approval is conditional on a confirmatory study whose protocol is due to the FDA by end of 2026.
Key Events · Product Development and Regulatory · INO
-
FDA Approves VOCERYQ for RRP
Accelerated approval to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis; 7 of 26 efficacy patients (27%) needed no surgical excision after 12 months.
-
Launch in ~60 Days
VOCERYQ is expected to be available to order and ship in approximately 60 days, with full field deployment in Q1 2027; 20 territories and Syneos Health support the rollout.
-
Conditional on Confirmatory Study
Continued approval may depend on verifying clinical benefit; a draft protocol is due to the FDA by end of 2026, with final alignment expected mid-2027, enrolling 50+ adult and pediatric patients.
-
First Revenue Against Tight Runway
This is the first commercial product for a company whose Q2 2026 10-Q carried a going concern warning with cash runway only into late Q1 2027 — launch timing now overlaps the funding gap.
Analysis · INO · Life Sciences
For a company that carried a going concern warning in August, this formal 8-K marking Inovio's first-ever FDA approval carries the commercial detail that matters. VOCERYQ (formerly INO-3107) is approved under accelerated approval to cut surgery frequency in adults with RRP, a population Inovio pegs at 25,000+ in the U.S. The drug can be ordered and shipped in roughly 60 days, with full field deployment in Q1 2027 — the first revenue line in the company's history. The catch: accelerated approval is conditional. A confirmatory study protocol is due to the FDA by end of 2026 and must be finalized by mid-2027, so the approval can be pulled if that study fails. With cash previously disclosed as lasting only into late Q1 2027, launch execution and any financing to fund the commercial build are now the whole story.
How filings like this one have moved
In the 30 days to Nov 2, 2026, 49.5% of the 190 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, INO was trading at $2.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.3M. The 52-week trading range was $0.56 to $2.72. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.